19/10/2019 12:31 am Welcome to isteroids.com - BLOG

Thursday 29, Jul 2010

  Tumor progression could be delayed with Avastin

Posted By
Pin it Share on Tumblr

Tumor progression could be delayed with AvastinA retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance has suggested that the use of Avastin to treat a subgroup of recurrent Grade 3 brain tumors is safe and effective at the same time.

Bevacizumab (also known as Avastin) emerges out as a potential therapy for gliomas, according to Marc Chamberlain, who is director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University of Washington School of Medicine and author of the study.

It is worthwhile to note here that Avastin is the first-approved therapy to inhibit angiogenesis, which is the process wherein new blood vessels are developed and important nutrients are transported to a tumor.

Saturday 19, Jun 2010

  Bevacizumab helpful in improving neurocognitive function with aggressive brain cancer

Posted By
Pin it Share on Tumblr

Bevacizumab helpful in improving neurocognitive function with aggressive brain cancerBevacizumab (Avastin) based therapy has the potential of making a real difference for patients with glioblastoma.

It was announced by Roche that phase II BRAIN study of bevacizumab alone or in combination with irinotecan chemotherapy for treating relapsed or progressive glioblastoma (GBM) suggested that the drug is effective.

As per William M. Burns, CEO of Roche’s Pharmaceuticals Division, Avastin is able to demonstrate its benefits for proving its worth as an effective treatment option for an increasing variety of cancers.

Monday 12, Apr 2010

  Macular edema managed by cancer treatment

Posted By
Pin it Share on Tumblr

Macular edema managed by cancer treatmentThe use of bevacizumab, popularly known as Avastin, for providing benefit to diabetic patients with macular edema as well as people who develop cystoid macular edema after cataract surgery has been reported by the journal Ophthalmology.

Bevacizumab is presently used to treat some forms of cancer.

It is important to note here that diffuse DME (DDME) is often resistant to laser and other standard treatments and treating DDME with bevacizumab is an amicable treatment options with no serious adverse effects.

Thursday 18, Feb 2010

  Avastin highly efficacious for recurrent glioblastoma patients

Posted By
Pin it Share on Tumblr

Avastin highly efficacious for recurrent glioblastoma patientsAvastin, taken alone or as a combination therapy, is highly effective in terms of improved response rates, survival rates, and progression-free survival times in patients suffering from recurrent glioblastoma, which is a deadly form of brain cancer.

It was remarked by Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study that a combination of Avastin and CPT-11 or Avastin alone has the ability to improve the response rate and overall survival to a significant extent.

It was further remarked by Cloughesy that the study findings can be termed as useful to treat patients with recurrent glioblastoma as Avastin is effective for reducing brain swelling and doses of steroids.

Sunday 07, Feb 2010

  Benefits of Avastin effective in delaying brain tumor progression

Posted By
Pin it Share on Tumblr

Benefits of Avastin effective in delaying brain tumor progressionAs per a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance, the usage of Avastin alone is safe as well as effective for delaying progression of brain tumor when it comes to treating a subgroup of recurrent Grade 3 brain tumors.

Avastin, known generically as bevacizumab, is the first-ever approved therapy for inhibiting angiogenesis.

Angiogenesis is the process by which new blood vessels are developed and transport vital nutrients to a tumor. It is important to note here that Avastin is approved for treating certain metastatic colon cancers and non-small cell lung cancer.

Marc Chamberlain, M.D., author of the study and director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University Of Washington School Of Medicine, said that Bevacizumab is an important drug of all of the targeted therapies for gliomas.

Sunday 07, Feb 2010

  Cancer treatment effective for managing diabetes-related edema and cataract surgery

Posted By
Pin it Share on Tumblr

Cancer treatment effective for managing diabetes-related edema and cataract surgeryThe journal Ophthalmology has reported on use of bevacizumab (Avastin) for providing relief to patients with macular edema and individuals with cystoid macular edema after cataract surgery.

Another study has described methods for enhancing the level of safety to make cataract surgery safer for diabetic retinopathy (DR) patients.

It is believed that diabetic retinopathy would be one of the greatest threats in the coming future with predictions for triple growth in such cases by the year 2050.

As per the Pan-American Collaborative Retina Study Group, led by J. Fernando Arevalo, MD, of the Caracas Central Ophthalmologic Clinic, Venezuela, treating DMME (diffused macular edema) with bevacizumab (Avastin), an anti-vascular endothelial growth factor (anti-VEGF) medication, is a better option though future studies in this regard to confirm efficacy and safety in treating these conditions.

Wednesday 27, Jan 2010

  Brain tumor progression in recurrent disease can be delayed by Avastin

Posted By
Pin it Share on Tumblr

Brain tumor progression in recurrent disease can be delayed by AvastinAccording to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance, the use of Avastin alone can prove to be an effective treatment option when it comes to curing a subgroup of recurrent Grade 3 brain tumors in terms of delaying tumor progression.

Avastin, known generically as bevacizumab, is the first-ever approved therapy that has been designed for inhibiting angiogenesis that is a process by which new blood vessels develop and transport important nutrients to a tumor.

Marc Chamberlain, M.D., author of the study published in the April 15 edition of the journal Cancer and director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University Of Washington School Of Medicine, said that bevacizumab has the unique potential of being the best palliative treatment.

Monday 04, Jan 2010

  Avastin helpful for delaying brain tumor progression

Posted By
Pin it Share on Tumblr

Avastin helpful for delaying brain tumor progressionAs per a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance, the usage of Avastin in alone can prove helpful in treating a subgroup of recurrent Grade 3 brain tumors.

It was revealed that this drug is not only safe but also effective in delaying progression.

Avastin, known generically as bevacizumab, is the first approved therapy that is designed for inhibiting angiogenesis.

Chamberlain, director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University Of Washington School Of Medicine, remarked that bevacizumab has the unique potential of being the most effective form of palliative treatment.

Friday 04, Dec 2009

  Avastin improves survival rates in patients affected by recurrent glioblastoma

Posted By
Pin it Share on Tumblr

Avastin improves survival rates in patients affected by recurrent glioblastomaThe targeted therapy Avastin, in a combination or isolation, has the capability of considerably increasing response rates, survival rates, and progression-free survival times in patients suffering from recurrent glioblastoma, a deadly form of brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study, remarked that Avastin alone and Avastin given with CPT-11 can improve the response rate and overall survival to a considerable extent.

Cloughesy remarked that the findings of this study constitute a huge breakthrough as Avastin has proved itself to be of great usefulness for treating patients with recurrent glioblastoma. It was also remarked that Avastin brings the level of brain swelling down and can even help in reducing the doses of steroids to ensure marked improvement in function.


Monday 19, Oct 2009

  Survival rate increased with Avastin in recurrent glioblastoma affected patients

Posted By
Pin it Share on Tumblr

Survival rate increased with Avastin in recurrent glioblastoma affected patientsAccording to a recent study that was conduced at 11 centers across the country and published in the early online version of the Journal of Clinical Oncology, survival rate gets increased with Avastin in recurrent glioblastoma affected patients. It was revealed during the study that the targeted therapy Avastin, alone or in combination with CPT-11 (chemotherapy drug) can considerably increase progression-free survival times and survival rates in patients with a deadly form of recurrent brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study said that positive results from Avastin have promoted the FDA to an accelerated approval of Avastin in May 2009 for use in patients with recurrent glioblastomas.

Avastin is an angiogenesis inhibitor that neutralizes VEGF (vascular endothelial growth factor), which is a chemical signal stimulating the growth of new blood vessels and has already been approved for use in metastatic colorectal, breast, and kidney cancers as well as non-small cell lung cancer.